Quick Take
Abpro (ABP) intends to raise $60 million from the sale of its common stock in a U.S. IPO, according to an amended registration statement.
The company is advancing a wide and diversified pipeline of immuno-oncology drug treatments for various diseases.
ABP hasn’t entered Phase 1 trials for its lead candidates, so is an early-stage company with a high-risk profile.
Company And Technology
Woburn, MA-based Abpro was founded in 2007 to focus on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. The company is developing a pipeline of antibodies (independently and through collaborations with global pharmaceutical and research institutions by leveraging proprietary DiversImmune and MultiMab antibody discovery and engineering platforms).
